Savara Inc. announced positive results from a clinical trial for their inhaled treatment for autoimmune pulmonary alveolar proteinosis (aPAP), with plans to submit a Biologics License Application to the FDA in 2025.
AI Assistant
SAVARA INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.